Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Go back to Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) Delayed: 26.38 --0 (-0%)
Previous Close $26.38    52 Week High $5.17 
Open $26.38    52 Week Low $0.94 
Day High $26.38    P/E N/A 
Day Low $26.38    EPS $0.00 
Volume 3,161